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In a previous report in CMI [1], we showed that
an ELISA for VlsE C6 peptide antibodies could
replace immunoblotting in the laboratory as a
conﬁrmatory test for Lyme borreliosis (LB) anti-
bodies following initial screening with an IgG
ELISA. When both tests were concordantly pos-
itive or negative, the combination reﬂected the
presence or absence of speciﬁc antibodies as
demonstrated by immunoblotting. According to
standard assays, the seropositivity level is high in
the normal population in this region [2]. This
makes the diagnosis of LB disease especially
difﬁcult. We now report how this modiﬁed two-
step antibody testing approach performs in the
clinical diagnostic setting. We also determined
whether serum C6 antibodies against Borrelia
burgdorferi s. l. would correlate better with
ongoing infection than the antibodies used
previously.
In total, 183 patients with suspicion of stage II
or III LB were studied. Clinical diagnosis was
based on the signs and symptoms listed by the
European Union Concerted Action on Lyme
Borreliosis (http://www.eucalb.com). The sero-
logical methods used for initial diagnosis were an
IgG ELISA (RecomWell Borrelia IgG; Mikrogen,
Martinsreid, Germany) and an immunoblot of
speciﬁc antibodies using recombinant antigens
(RecomBlot; Mikrogen). The effect on post-test
probability was considered low with a positive
likelihood ratio (PLR) of 1.5–2. If inconclusive
results were obtained, a second analysis after a
further 4–6 weeks was performed. If intrathecal
production of speciﬁc antibodies was detected,
the PLR was scored as 10. These methods were
used for pre-test classiﬁcation of disease probab-
ility, which was performed after a 1-year follow-
up period. The C6 antibody analysis method was
performed as described previously [1], with the
results blinded until the end of the study.
Sensitivity, speciﬁcity, positive predictive
value, PLR, negative likelihood ratio, 95% CIs,
signiﬁcance testing by v2, regression and receiver
operating characteristic were calculated by stand-
ard methods. The group of ‘deﬁnitely not’ LB
patients was used as the reference standard for
calculations. The clinical probability of LB was
graded as deﬁnite (>0.8), high (0.5–0.8), medium
(0.2–0.4), low (<0.2) or not LB. The test results for
these groups are shown in Tables 1 and 2. The
difference in sensitivity between the C6-positive
fractions was signiﬁcant (p £ 0.05–£ 0.001) for the
deﬁnite, high-probability and medium-probabil-
ity groups. The correlation with disease probab-
ility was signiﬁcant (p £ 0.001; r = 0.96 for C6
alone; r = 0.98 for the combination).
Assay of C6 antibodies clearly improved the
diagnostic performance for the group with deﬁn-
ite LB. The combination of C6 and IgG ELISA
tests was marginally better in the calculations,
with the reservation that IgG ELISA was also
included in the standard diagnostic process.
Analysis of the receiver operating characteristic
showed an area under the curve of 0.76, with a
sensitivity of 0.71 and a speciﬁcity of 0.68. The C6
Table 1. Diagnostic performance of the C6 assay, the C6
assay with the IgG ELISA, and the IgG ELISA with the
immunoblot assay, with each of the clinical subgroups for
the diagnosis of Lyme borreliosis (LB)a
Diagnostic
groups
Sensitivity (95% CI)
C6 antibodyb
C6 antibody and
IgG ELISAc
IgG ELISA and
immunoblotd
Deﬁnite LB 1.0 (0.94–1.0) 0.94 (0.87–1.0 0.94 (0.87–1.0)
High probability 0.75 (0.62–0.88) 0.75 (0.62–0.88) 1.0 (0.97–1.0)
Medium probability 0.69 (0.56–0.82) 0.67 (0.53–0.80) 1.0 (0.97–1.0)
Low probability 0.46 (0.31–0.60) 0.46 (0.31–0.60) 0.96 (0.90–1.0)
Not LB (positive fraction) 0.44 (0.27–0.66) 0.32 (0.16–0.48) 0.56 (0.27–0.61)
aStandard serology (IgG ELISA + immunoblot), but not C6 antibody, was included
in the diagnostic process.
bSpeciﬁcity 0.56 (95% CI, 0.39–0.73).
cSpeciﬁcity 0.68 (95% CI, 0.52–0.83).
dSpeciﬁcity 0.44 (95% CI, 0.27–0.61).
Table 2. Diagnostic performance parameters for the C6
assay alone and in combination with the IgG ELISA
Deﬁnite LB
High
probability
Medium
probability
Low
probability
C6 antibody
PPV
(95% CI)
0.70 (0.54–0.83) 0.50 (0.32–0.68) 0.69 (0.56–0.82) 0.58 (0.42–0.74)
PLR
(95% CI)
2.20 (1.50–3.23) 1.70 (1.08–2.68) 1.56 (1.02–2.31) 1.03 (0.63–1.69)
NLR
(95% CI)
0.05 (0.01–0.30) 0.45 (0.20–1.01) 0.56 (0.33–0.94) 0.97 (0.65–1.45)
C6 antibody and IgG ELISA
PPV
(95% CI)
0.75 (0.62–0.88) 0.58 (0.39–0.77) 0.74 (0.61–0.87) 0.66 (0.49–0.82)
PLR
(95% CI)
2.94 (1.78–4.77) 2.32 (1.34–4.01) 2.06 (1.22–3.49) 1.41 (0.79–2.52)
NLR
(95% CI)
0.08 (0.02–0.33) 0.45 (0.20–1.01) 0.49 (0.31–0.78) 0.80 (0.56–1.14)
PPV, positive predictive value; PLR, positive likelihood ratio; NLR, negative
likelihood ratio.
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analysis, alone and in combination with IgG
ELISA, improved the diagnosis of LB by a PLR
of 2–3 compared with the standard two-step
serological approach. This provides a clear
advantage, especially for clinical material with
a high background level of seropositivity,
when difﬁculties are met that are not encountered
when dealing with sporadic cases of Borrelia
infection. However, the above calculations are
not appropriate for areas with a low prevalence
of LB.
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Bacteraemia in cancer patients caused by
colistin-resistant Gram-negative bacilli after
previous exposure to ciproﬂoxacin and ⁄or
colistin
10.1111/j.1469-0691.2006.01364.x
The recent publication in CMI by Michalopoulos
et al. [1], as well as that of Li et al. [2], focused on
the increasing role of colistin (COL) for the
treatment of infections caused by multiresistant
Gram-negative bacilli. COL has been reported to
be the only antibiotic effective against multire-
sistant strains of Pseudomonas aeruginosa or Acine-
tobacter baumanii in cases when all other available
antibiotics, including carbapenems, were ineffec-
tive [1,2]. However, Landman et al. [3] reported
the emergence of resistance to polymyxin B in 13
patients with P. aeruginosa (PA) infection in the
USA, with MICs up to 8 mg ⁄L.
As long ago as 1995, we described an outbreak
of meropenem-resistant P. aeruginosa infections in
a cancer centre, in which >15 patients were
infected with bacteraemia caused by P. aeruginosa
susceptible only to COL and amikacin [4].
Between October 2004 and July 2005, we observed
ten patients in the intensive care unit (ICU) of
St Elisabeth Cancer Institute, Bratislava, Slovakia,
who were hospitalised with post-operative peri-
tonitis (wound infection and bacteraemia) and
infected with COL-resistant Gram-negative bac-
teria. The ﬁrst patient was admitted to the ICU in
September 2004, and was infected initially with
P. aeruginosa with a COL MIC of 4 mg ⁄L, which
increased after therapy to 8 mg ⁄L. Eight of the ten
patients stayed in the ICU on several occasions,
all ten were treated previously with ciproﬂoxacin,
and ﬁve with colistin. Five of the ten patients died
(four with uncontrolled sepsis; one with under-
lying disease and bacteraemia).
Eighteen COL-resistant organisms were isolat-
ed within the context of polymicrobial bacterae-
mia (Table 1). Previous exposure to colistin and
ciproﬂoxacin probably inﬂuenced the develop-
ment of resistance. Two species (P. aeruginosa,
Citrobacter freundii; patient 3) showed stepwise
increases in MICs (from 0.25 or 2 to 8 mg ⁄L)
during treatment with colistin (Table 1). For the
remaining patients (16 organisms), the bacterial
isolates were resistant (MICs 8–64 mg ⁄L) on ﬁrst
isolation (Table 1). The recommended breakpoint
MIC for colistin is 2 mg ⁄L in France, 4–8 mg ⁄L in
the UK, 4–8 mg ⁄L according to the NCCLS, and
4 mg ⁄L in Germany [2]. Therefore we considered
isolates with an MIC ‡ 8 mg ⁄L to be resistant.
DNA ﬁngerprinting was not performed, but none
of the resistance phenotypes were identical, and
we therefore assumed that each isolate was
different. For eight patients, none of the tested
antibiotics retained in-vitro activity, and ﬁve of
these patients died. Emerging resistance in our
hospital to COL provides further evidence for the
onset of the post-antibiotic era in P. aeruginosa,
Stenotrophomonas maltophilia and some Enterobac-
teriaceae.
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